Radiation therapy for adjunctive treatment of adrenal cortical carcinoma

• Published in: American journal of clinical oncology Vol. 14; no. 2; p. 170
• Main Authors: Markoe, A M, Serber, W, Micaily, B, Brady, L W
• Format: Journal Article
• Language: English
• Published: United States 01.04.1991
• Subjects: Adrenal Gland Neoplasms - radiotherapy; Adrenal Gland Neoplasms - surgery; Aged; Aged, 80 and over; Carcinoma - radiotherapy; Carcinoma - secondary; Carcinoma - surgery; Child; Combined Modality Therapy; Female; Humans; Lymph Nodes - radiation effects; Male; Middle Aged; Mitotane - therapeutic use; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Radiotherapy Dosage; Survival Rate
• ISSN: 0277-3732
• DOI: 10.1097/00000421-199104000-00015

Adrenocortical carcinoma is a rare disease which is primarily approached surgically. There have been few reports of the efficacy of radiation therapy and, for the most part, these have been anecdotal. This paper reports on the potential adjuvant role of radiation therapy after surgical excision of primary adrenal cortical carcinoma and also comments about the efficacy of palliative radiation therapy for metastases. We have identified eight patients treated for adrenal cortical carcinomas at Hahnemann University Hospital (HUH) from 1962 until the present and have also identified five patients with the same diagnosis at Philadelphia General Hospital (PGH) from 1962 until its close in 1975. These two groups are examined separately. In the PGH group, in which two patients were diagnosed at autopsy and only one patient was treated by radiation therapy, the median survival was between 0 and 1 month for Stage IV disease with the only patient surviving to 6 months being that patient receiving radiation therapy. In the HUH group, five of eight patients were treated adjunctively after diagnosis, one was not and two received palliative therapy. The median survival for treated Stage III patients was between 34 months and 7 years. The suggestion, based on a limited patient series, is that patients treated postoperatively to the tumor bed and nodal areas in Stage III disease may have improved survival over historic series and improved local control.